雅虎香港 搜尋

搜尋結果

  1. 2018年3月8日 · Vaxigrip Tetra ® (Sanofi Pasteur) is a novel four-strain influenza vaccine belonging to the Vaxigrip ® family of influenza vaccines []. It is a quadrivalent split-virion inactivated influenza vaccine containing the purified HA and NA antigens from the four influenza virus strains recommended by the WHO [ 79 ].

  2. 2008 2009 Seasonal Human Influenza Virus Vaccine Vaxigrip, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more

  3. 2013年1月31日 · Ten MAbs also showed reactivity with Vaxigrip (2009–10) whereas none of the MAbs reacted with rHA of seasonal H1N1 (A/Solomon Islands/03/2006) and ovalbumin, used as negative control. The culture supernatants of 2 MAbs (MA2076 and MA2077) reacting with the pandemic H1N1 rHA were tested in a microneutralization assay with homologous virus.

  4. mein.sanofi.de › produkte › vaxigrip-tetraVaxigrip Tetra® - Sanofi

    Produkte & Darreichungsform. VAXIGRIP Tetra 2023/2024 Inj.Susp.Fertigspr.o.Kan. VAXIGRIP Tetra 2023/2024 Inj.Susp.Fertigspr.m.Kan. FAQ – Häufig gestellte Fragen zu Vaxigrip Tetra finden Sie bei Sanofi Medical Information. Bitte beachten Sie, dass sich im Markt noch Packungen mit früheren Versionen der Packungsbeilage befinden können.

  5. 院舍防疫注射計劃 接種疫苗的好處 由季節性流感或肺炎球菌所引起的呼吸道感染是常見的疾病,而免疫力較低的人和長者一旦染上流感,可能會出現嚴重併發症,嚴重時更可導致死亡。當流感大流行時,繼發性細菌性肺炎是導致患病和死亡的重要原因。接種疫苗是其中一種預防季節性流感、肺炎 ...

  6. Vaxigrip Tetra is indicated for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine for:,- active immunisation of adults, including pregnant women, and children from 6 months of age and older,- passive protection of infant (s) from birth to less than 6 ...

  7. Effets secondaires Vaxigriptetra. Comme tous les médicaments, ce vaccin peut provoquer des effets indésirables, mais ils ne surviennent pas systématiquement chez tout le monde. Très fréquent (pouvant affecter plus d'une personne sur 10) : Maux de tête, douleurs musculaires (myalgies), malaise (1), douleur au site d'injection.